In conclusion, our results identified a deregulated PRC1 component, CBX2 and established an association between CBX2, tumor progression, and resistance to DNA damage treatment, providing some evidence for future targeted therapy against CBX2 in cervical cancer. Here, PRC1 is linked to neoplasm.